Milestone Pharmaceuticals, Inc. (MIST)
1.04
-0.02
(-1.42%)
USD |
NASDAQ |
Aug 24, 16:00
1.05
+0.01
(+0.96%)
After-Hours: 20:00
Milestone Pharmaceuticals Debt to Equity Ratio : 7.785 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 7.785 |
| March 31, 2026 | 3.810 |
| December 31, 2025 | 1.398 |
| September 30, 2025 | 2.790 |
| June 30, 2025 | -3.178 |
| March 31, 2025 | -9.078 |
| December 31, 2024 | 4.168 |
| September 30, 2024 | 2.250 |
| June 30, 2024 | 1.665 |
| March 31, 2024 | 1.315 |
| December 31, 2023 | 3.087 |
| September 30, 2023 | 1.790 |
| June 30, 2023 | 1.245 |
| March 31, 2023 | 0.9213 |
| December 31, 2022 | 0.0375 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.0334 |
| June 30, 2022 | 0.0064 |
| March 31, 2022 | 0.0063 |
| December 31, 2021 | 0.0062 |
| September 30, 2021 | 0.006 |
| June 30, 2021 | 0.006 |
| March 31, 2021 | 0.0067 |
| December 31, 2020 | 0.0066 |
| September 30, 2020 | 0.0093 |
| June 30, 2020 | 0.0033 |
| March 31, 2020 | 0.0036 |
| December 31, 2019 | 0.0045 |
| September 30, 2019 | 0.0044 |
| June 30, 2019 | 0.0016 |
| March 31, 2019 | 0.0037 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| InMed Pharmaceuticals, Inc. | 0.061 |
| NervGen Pharma Corp. | 0.00 |
| Clearmind Medicine, Inc. | 0.0075 |
| Lexaria Bioscience Corp. | 0.0183 |
| Target Group, Inc. (Canada) | -1.291 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 181.62M |
| Total Liabilities (Quarterly) | 163.41M |
| Shareholders Equity (Quarterly) | 18.22M |
| Current Ratio | 8.129 |
| Net Debt Paydown Yield | -10.34% |